GANYMED PHARMACEUTICALS AG;TRON - TRANSLATIONALE ONKOLOGIE AN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
发明人:
SAHIN UGUR,TÜRECI ÖZLEM,MITNACHT-KRAUS RITA,JACOBS STEFAN DENIS,UTSCH MAGDALENA JADWIGA,HEINZ CORNELIA ADRIANA MARIA,STADLER CHRISTIANE REGINA
申请号：
NZ70158513
公开号：
NZ701585A
申请日:
2013.05.21
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
The present invention provides a combination therapy combination therapy comprising an antibody having the ability of binding to CLDN18.2 with an agent stabilizing or increasing expression of CLDN18.2 for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
